AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Seattle biotechnology firm's cancer therapy shows strongest effect yet.
Byline: Luke Timmerman
Oct. 29--Dendreon has been working for a dozen years to dramatically change the treatment of prostate cancer by creating a life-extending therapy with mild side effects. Yesterday, the company rolled out the strongest ammunition yet to show it could become reality.
The small Seattle biotech company said its cancer vaccine, Provenge, was able to significantly extend lives across a study group of 127 terminal prostate-cancer patients, after three years of follow-up examination. The company's stock leapt 24 percent after the news to close at $9.85.
Dendreon did not release full statistical details from the clinical trial, choosing to save them for a prestigious peer-reviewed medical journal and to make waves at a medical meeting.
But in a conference call with Wall Street analysts, the company said Provenge…
- Dendreon Announces Results of D9905 Phase 2 Study of Provenge in Patients with...
- Press release article from: PR Newswire May 24, 2005 700+ words
...dependent prostate cancer). Provenge is the Company...is examining Provenge in patients...dependent prostate cancer." Study Details...efficacy of Provenge to treat men suffering from prostate cancer, risks and...
- Dendreon Corporation Presents Provenge Data at Prostate Cancer Foundation...
- Press release article from: Business Wire November 10, 2003 700+ words
...Trial of APC8015 (Provenge) in Androgen Independent Prostate Cancer" provided an...our promising Provenge data at the prestigious Prostate Cancer Foundation meeting...treatments for prostate cancer." Provenge is currently in...
- Dendreon Completes Enrollment in Phase 3 PROTECT (P-11) Clinical Trial of...
- Press release article from: PR Newswire June 21, 2005 700+ words
...sensitive) prostate cancer. Provenge is the Company...refractory) prostate cancer when compared...receiving placebo. Provenge is being further...efficacy of Provenge to treat men suffering from prostate cancer, risks and...
- Dendreon's Second Randomized Phase 3 D9902A Trial Shows Provenge Extends...
- News wire article from: The America's Intelligence Wire July 21, 2005 700+ words
...Phase III studies of Provenge focused on men with androgen-independent prostate cancer. Provenge is an investigational...controlled study of Provenge in 127 men with asymptomatic...androgen-independent prostate cancer. The 9901 protocol...
- Dendreon's Second Randomized Phase 3 D9902A Trial Shows Provenge Extends...
- News wire article from: Fair Disclosure Wire July 21, 2005 700+ words
...Phase III studies of Provenge focused on men with androgen-independent prostate cancer. Provenge is an investigational...controlled study of Provenge in 127 men with asymptomatic...androgen-independent prostate cancer. The 9901 protocol...
- Dendreon Confirms Over 95 Percent of Prostate Cancer Patients Express Key...
- Press release article from: Business Wire April 8, 2002 700+ words
...highly expressed in prostate cancer. Provenge is Dendreon's investigational...therapeutic vaccine for prostate cancer, currently in Phase...enrollment in trials of Provenge for the treatment of androgen independent prostate cancer. Less than 5 percent...
- Dendreon Reports Combination of Provenge and Avastin Impacts PSA Doubling Time...
- Press release article from: PR Newswire February 20, 2005 700+ words
...patients with prostate cancer that had relapsed...radiation therapy. Provenge is the Company...alternative for prostate cancer patients." Provenge is an active...efficacy of Provenge to treat men suffering from prostate cancer, risks and...
- PROVENGE/AVASTIN IMPACT PSA DOUBLING TIME IN PROSTATE CANCER.
- Newspaper article from: Biotech Business April 1, 2004 700+ words
...in patients with prostate cancer that had relapsed...radiation therapy. Provenge is the company...the treatment of prostate cancer. The data were...alternative for prostate cancer patients." Provenge is an active immunotherapy...
- Dendreon announces Provenge significantly improves survival in men with...
- News wire article from: Asia Africa Intelligence Wire February 17, 2005 700+ words
...Corp announced that Provenge, the company's...the treatment of prostate cancer, significantly improved...four-week period. Provenge is designed to stimulate...immune system against prostate cancer. Provenge is being further...
- Dendreon Corporation Receives Additional Patent for Provenge Prostate Cancer...
- Press release article from: Business Wire April 19, 2001 700+ words
...therapeutic composition of Provenge(TM) -- its lead...treatment of advanced prostate cancer. Provenge is composed of a...vaccine therapy." Provenge is currently in double...hormone refractory prostate cancer. More than 30 medical...
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA
The AccessMyLibrary advertising network includes:
